We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+33.56%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$4.23B
AUM Growth
+$1.6B
Cap. Flow
+$897M
Cap. Flow %
21.18%
Top 10 Hldgs %
21.32%
Holding
1,176
New
232
Increased
605
Reduced
167
Closed
168

Top Buys

Rank Stock Value
1
BEKE icon
KE Holdings
BEKE
+$84.9M
2
LU icon
Lufax Holding
LU
+$59.6M
3
BABA icon
Alibaba
BABA
+$42.6M
4
JD icon
JD.com
JD
+$41.5M
5
GRPN icon
Groupon
GRPN
+$36.4M

Top Sells

Rank Stock Value
1
PTON icon
Peloton Interactive
PTON
+$25.2M
2
JMIA
Jumia Technologies
JMIA
+$21.7M
3
MTCH icon
Match Group
MTCH
+$20.5M
4
FVRR icon
Fiverr
FVRR
+$15.4M
5
SFIX
Stitch Fix
SFIX
+$10.7M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 34.91%
2 Technology 23.48%
3 Communication Services 13.86%
4 Financials 4.63%
5 Real Estate 4.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGNE icon
901
Neurogene
NGNE
$712M
$13K ﹤0.01%
+49
New +$12K
SIGA icon
902
SIGA Technologies
SIGA
$219M
$13K ﹤0.01%
1,875
+1,209
+182% +$8.52K
TECX
903
Tectonic Therapeutic
TECX
$606M
$13K ﹤0.01%
79
+53
+204% +$9.42K
EGRX
904
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$13K ﹤0.01%
300
+182
+154% +$8.51K
FLXN
905
DELISTED
Flexion Therapeutics, Inc.
FLXN
$13K ﹤0.01%
1,155
+735
+175% +$8.54K
AFMD
906
DELISTED
Affimed
AFMD
$12K ﹤0.01%
211
+139
+193% +$6.54K
RLMD icon
907
Relmada Therapeutics
RLMD
$527M
$12K ﹤0.01%
+375
New +$12.9K
SPRO icon
908
Spero Therapeutics
SPRO
$73M
$12K ﹤0.01%
+625
New +$9.74K
TCRT icon
909
Alaunos Therapeutics
TCRT
$4.86M
$12K ﹤0.01%
+33
New +$13.1K
XENE icon
910
Xenon Pharmaceuticals
XENE
$6.12B
$12K ﹤0.01%
+805
New +$9.42K
APLT
911
DELISTED
Applied Therapeutics
APLT
$11K ﹤0.01%
+515
New +$10.7K
BYND icon
912
Beyond Meat
BYND
$277M
$11K ﹤0.01%
95
-2,714
-97% -$409K
CLLS
913
Cellectis
CLLS
$285M
$11K ﹤0.01%
410
+256
+166% +$5.74K
GERN icon
914
Geron
GERN
$949M
$11K ﹤0.01%
7,370
+4,718
+178% +$8.6K
INZY
915
DELISTED
Inozyme Pharma
INZY
$11K ﹤0.01%
+535
New +$12.7K
MSA icon
916
Mine Safety
MSA
$7.49B
$11K ﹤0.01%
75
+41
+121% +$5.92K
RAPT
917
DELISTED
RAPT Therapeutics
RAPT
$11K ﹤0.01%
+71
New +$15.4K
QTTB icon
918
Q32 Bio
QTTB
$464M
$11K ﹤0.01%
58
+37
+176% +$7.15K
SYRS
919
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11K ﹤0.01%
105
+66
+169% +$6.02K
FUSN
920
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$11K ﹤0.01%
+955
New +$12K
BCEL
921
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$11K ﹤0.01%
690
+440
+176% +$6.6K
SPPI
922
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$11K ﹤0.01%
3,400
+2,154
+173% +$8.87K
CRNX icon
923
Crinetics Pharmaceuticals
CRNX
$8.92B
$10K ﹤0.01%
+755
New +$10.5K
DTIL icon
924
Precision BioSciences
DTIL
$207M
$10K ﹤0.01%
40
+25
+167% +$6.13K
INGR icon
925
Ingredion
INGR
$6.58B
$10K ﹤0.01%
136
+34
+33% +$2.62K
35 36
37
38 39

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Penserra Capital Management held 1,176 positions worth $4.23B, up 61% from $2.63B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Penserra Capital Management deployed $897M of net new capital in Q4 2020, opening 232 new positions and adding to 605 existing holdings. Its largest new stake was KE Holdings: 1,278,021 shares worth $78.6M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, down from 35% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Peloton Interactive, an estimated $25.2M trimmed.

  • Penserra Capital Management's largest Q4 2020 buy was KE Holdings: 1,278,021 shares worth $78.6M.
  • Penserra Capital Management added most to Alibaba in Q4 2020, an estimated $42.6M increase.
  • Penserra Capital Management's biggest Q4 2020 reduction was Peloton Interactive, cutting an estimated $25.2M.
  • Penserra Capital Management fully exited Palomar in Q4 2020, selling an estimated $6.65M.
  • Penserra Capital Management's ten largest holdings make up 21% of its $4.23B portfolio in Q4 2020.
  • Penserra Capital Management opened 232 new positions and closed 168 in Q4 2020.
  • Penserra Capital Management's portfolio value rose 61% quarter-over-quarter to $4.23B.

Based on Penserra Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.